Unique high throughput screen for the in vitro prediction of phospholipidosis and comprehensive physicochemical profiling

Get rid of the time consuming, poorly reproducible and costly cell based assays

Poor ADME/Tox properties are the major reason for the failure of NCEs in pharmaceutical R&D. This can be extremely costly, in particular, if such adverse effects such as induction of phospholipidosis or serious CNS side-effects manifest just in clinical trials. Accordingly, there is an increasing pressure to screen compound libraries and NCEs for their ADME/Tox properties in vitro, preferably already before lead optimization.

The Kibron PLDscreen is a new unique biophysical screen for the prediction of the ability of compounds to induce phospholipidosis. PLDscreen yields an accuracy corresponding to in vivo data, a high throughput with minimal compound volumes, resulting in a fast, reliable and cost-efficient screening of PLD.

Take your R&D beyond PAMPA and PSA

One of the key tasks in ADME research is to identify compounds that will pass passively through the plasma membrane surrounding cells. Additionally to PLD screening, the Kibron PLDscreen allows for comprehensive physicochemical profiling of compounds, by providing the parameters Kaw (lipophilicity), TSA (true surface area), CMC (critical micelle concentration) and pKa (surface ionization constant), further correlating with ADME properties such as BBB permeation.

The Kibron PLDscreen enables recognition of potentially problematic compounds in the lead optimization and diminishes greatly the need for animal tests.